// App-Quantinova.ai

CTIM-13 : PHASE 1 CLINICAL TRIAL OF ONCOLYTIC VIRAL IMMUNOTHERAPY WITH CAN-2409 + VALACYCLOVIR IN COMBINATION WITH NIVOLUMAB AND STANDARD OF CARE (SOC) IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG)

Researchers

Presenter

  • Patrick Wen

Principal Investigators

  • Xiaobu Ye

  • David Reardon

  • Wenya Linda Bi

  • Pierpaolo Peruzzi

  • Nirav Patel

  • Roy Strowd

  • Stephen Tatter

  • Ian Lee

  • Tobias Walbert

  • James Snyder

  • Steven Brem

  • Arati Desai

  • Stephen Bagley

  • Nduka Amankulor

  • Frank Lieberman

  • Megan Mantica

  • Lenika Lopez

  • Susan Bell

  • Andrea Manzanera

  • Francesca Barone

  • Brian Guzik

  • Sean Lawler

  • Lixian Jin

  • William Timmer

  • Neeraja Danda

  • Serena Desideri

  • L Burt Nabors

  • Stuart Grossman

  • Estuardo Aguilar-Cordova

  • Paul Peter Tak

  • E Antonio Chiocca

Medical Centers

  • Candel Therapeutics, Powell, OH, USA

  • Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

  • Harvey Cushing Neurooncology Laboratories, Department of Neurosurgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA

  • Johns Hopkins University, Baltimore, MD, USA

  • Bristol-Myers Squibb, Lawrenceville, NJ, USA

  • Dana-Farber/Brigham and Women's Cancer Center, Boston, MA

  • The University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

  • University of Alabama, Birmingham, Birmingham, AL, USA

  • henry ford hospital, detroit, MI, USA

  • University of Pennsylvania, Philadelphia, PA, USA

  • The Harvey Cushing Neuro-Oncology Laboratories, Boston, USA

  • Clinical Grants and Contracts Branch, National Cancer Institute, Bethesda, MD, USA

  • Wake Forest School of Medicine, Winston-Salem, NC, USA

  • Dana-Farber Cancer Institute, Boston, MA, USA, Boston, MA, USA

  • UPMC Hillman Cancer Center, Pittsburgh, PA, USA

  • BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

  • Wake Forest University, Winstom-Salem, NC, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • High-Grade Gliomas

Biomarkers

  • N/A

Drug/Treatment

  • Zelitrex

  • Temozolomide

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved